Emergent BioSolutions Announces Appointment of Sujata Dayal to Board of Directors
07 July 2022 - 6:05AM
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the
company’s board of directors appointed Sujata Dayal as a Class II
director to serve on the board effective July 15, 2022, with an
initial term expiring at the 2023 annual meeting of stockholders.
Ms. Dayal was also appointed as a member of both the Nominating and
Corporate Governance Committee and the Special Committee on
Manufacturing and Quality Oversight.
“We are pleased to welcome Sujata Dayal to
Emergent’s Board of Directors,” said Zsolt Harsanyi, Ph.D.,
chairman of the board of Emergent BioSolutions. “Sujata’s deep
experience in healthcare compliance and strong expertise in legal
and regulatory oversight will be invaluable to Emergent as we
continue to grow the business and pursue our mission. We look
forward to her contributions.”
“I am enthusiastic to serve on the board of a
company that is focused on public health with a mission to protect
and enhance life,” said Ms. Dayal. “As Emergent executes on its
strategy, I am delighted with the opportunity to contribute my
passions in healthcare compliance and working with fellow directors
and the management team to advance the company.”
Ms. Dayal has served as vice president and global
chief compliance officer of Medline Industries, Inc. since March
2020. Over the last two decades, Ms. Dayal has held roles of
growing responsibility in compliance with a focus on healthcare
compliance in the pharmaceutical and medical device industry. She
previously served as a vice president, healthcare compliance at
Johnson & Johnson from 2013 to 2020. Prior to that, she served
on senior executive roles in ethics and compliance at Biomet, Inc.
and Abbott Laboratories.
Ms. Dayal is an attorney by training with
expertise in transactional work, regulatory law, privacy and
compliance, including healthcare compliance and anti-corruption.
She earned her J.D. from Chicago-Kent College of Law, LL.M. from
Columbia University School of Law, LL.B. from Rajasthan University
Law School in Jaipur, India, and B.A. Honors degree in Political
Science from Lady Shri Ram College in New Delhi, India.
About Emergent BioSolutions At
Emergent, our mission is to protect and enhance life. For over 20
years, we’ve been at work defending people from things we hope will
never happen—so we are prepared just in case they ever do. We
provide solutions for complex and urgent public health threats
through a portfolio of vaccines and therapeutics that we develop
and manufacture for governments and consumers. We also offer a
range of integrated contract development and manufacturing services
for pharmaceutical and biotechnology customers. To learn more about
how we plan to protect or enhance 1 billion lives by 2030, visit
our website and follow us on LinkedIn, Twitter, and Instagram.
Safe Harbor Statement This press
release includes forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Any
statements, other than statements of historical fact, including,
but no limited to, statements regarding executing on our growth
strategy and advancing the company, are forward-looking statements.
These forward-looking statements are based on our current
intentions, beliefs and expectations regarding future events. We
cannot guarantee that any forward-looking statement will be
accurate. Investors should realize that if underlying assumptions
prove inaccurate or unknown risks or uncertainties materialize,
actual results could differ materially from our expectations.
Investors are, therefore, cautioned not to place undue reliance on
any forward-looking statement. Any forward-looking statement speaks
only as of the date of this press release, and, except as required
by law, we do not undertake to update any forward-looking statement
to reflect new information, events or circumstances. There are a
number of important factors that could cause our actual results to
differ materially from those indicated by such forward-looking
statements. Investors should consider this cautionary statement as
well as the risk factors identified in our periodic reports filed
with the Securities and Exchange Commission when evaluating our
forward-looking statements.
Investor Contact: Robert G.
Burrows Vice President, Investor Relations 240-631-3280
burrowsr@ebsi.com
Media Contact: Matt Hartwig Senior
Director, Media Relations mediarelations@ebsi.com
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Apr 2024 to May 2024
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From May 2023 to May 2024